Edition:
United Kingdom

Lilly Announces Top-Line Phase 3 Results For Oral JAK Inhibitor Baricitinib, In Combination With Topical Corticosteroids In Adult Patients With Moderate To Severe Atopic Dermatitis


Friday, 23 Aug 2019 

Aug 23 (Reuters) - Eli Lilly And Co::LILLY ANNOUNCES TOP-LINE PHASE 3 RESULTS FOR ORAL JAK INHIBITOR BARICITINIB, IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS.ELI LILLY AND CO - BARICITINIB MET PRIMARY ENDPOINT IN BREEZE-AD7, THIRD PIVOTAL PHASE 3 TRIAL IN BREEZE-AD PROGRAM TO BE COMPLETED IN 2019.ELI LILLY AND CO - MOST COMMON TREATMENT-EMERGENT ADVERSE EVENTS OBSERVED WERE NASOPHARYNGITIS, UPPER RESPIRATORY TRACT INFECTION AND FOLLICULITIS.ELI LILLY AND CO - SAFETY DATA WERE CONSISTENT WITH KNOWN SAFETY PROFILE OF BARICITINIB.ELI LILLY AND CO - NO MALIGNANCIES, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), OR DEATHS WERE REPORTED IN STUDY.